Select Page

Future Studies

— Multiple Sclerosis –

 MedDay  SPI2

Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study

Novartis COMB157G2301 (ASCLEPIOS I)

A randomized, double-blind, double-dummy, parallel-group study  comparing the efficacy and safety of ofatumumab versus  teriflunomide in patients with relapsing multiple sclerosis

Roche MA30143 (ENSEMBLE)

An open-label, single-arm study to evaluate the effectiveness and safety of ocrelizumab in patients with relapsing multiple sclerosis

Amyotrophic Lateral Sclerosis

Neuraltus NP001-10-003

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation


— Brain tumor

Intrago II

A Multicenter, Randomized Phase III Study on Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma multiforme (Intrago II)

 — Parkinson —


A double-blind, randomized study of the effectiveness of the Portable Neuromodulation Stimulator (PoNS™) 4.0 device for cranial nerve noninvasive neuromodulation (CN-NINM) in subjects with Parkinson’s disease

— Alzheimer’s disease and Dementia —

Frontotemporal Dementia-BioBank Dr. Ducharme

Prospective Study of Single Subject Cortical Thickness as an Early Diagnostic Biomarker of Frontotemporal Dementia

— Spine Surgery —


 “MASC” -Minocycline in Acute Spinal Cord Injury

 — Vascular–